Christopher Yea - Kalvista Pharmaceuticals Chief Development Officer
| KALV Stock | USD 8.64 0.08 0.93% |
Executive
Mr. Christopher M. Yea, Ph.D., is the Chief Development Officer of of the Company. since November 2015 and became our Chief Development Officer as of November 2016 in connection with the reverse acquisition transaction. Prior to joining us, he was the Chief Operating Officer at Vantia, Ltd. from its spinout from Ferring Pharmaceuticals in 2008, until November 2015. Prior to the spinout of Vantia, Dr. Yea led the Biology group and was responsible for transition of candidates into development at Ferring Pharmaceuticals. Following postdoctoral work he spent several years at RousselUCLAF and Hoechst Marion Roussel since 2016.
| Age | 61 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 55 Cambridge Parkway, Cambridge, MA, United States, 02142 |
| Phone | 857 999 0075 |
| Web | https://www.kalvista.com |
Latest Insider Transactions
Yea holds a B. Sc. and Ph.D. in Biochemistry from the University of Bristol, UK.Christopher Yea Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Yea against Kalvista Pharmaceuticals stock is an integral part of due diligence when investing in Kalvista Pharmaceuticals. Christopher Yea insider activity provides valuable insight into whether Kalvista Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Kalvista Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kalvista Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Yea over two months ago Disposition of 3125 shares by Christopher Yea of Kalvista Pharmaceuticals subject to Rule 16b-3 | ||
Christopher Yea over three months ago Disposition of 1916 shares by Christopher Yea of Kalvista Pharmaceuticals at 12.4 subject to Rule 16b-3 | ||
Christopher Yea over three months ago Disposition of 3125 shares by Christopher Yea of Kalvista Pharmaceuticals subject to Rule 16b-3 | ||
Christopher Yea over three months ago Disposition of 7102 shares by Christopher Yea of Kalvista Pharmaceuticals at 12.0133 subject to Rule 16b-3 |
Kalvista Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5394) % which means that it has lost $0.5394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9084) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.17 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.03). At this time, Kalvista Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 11.7 M in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.03).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Marc CPA | Crinetics Pharmaceuticals | 45 | |
| Anthony Casciano | Viridian Therapeutics | 48 | |
| Evan JD | Cogent Biosciences | 45 | |
| Steven JD | Cytokinetics | 66 | |
| Robert Richard | Lyra Therapeutics | 67 | |
| Allison JD | Kronos Bio | 42 | |
| MBA MD | Dyne Therapeutics | 58 | |
| Christi Waarich | Cogent Biosciences | N/A | |
| Robert MD | Crinetics Pharmaceuticals | N/A | |
| Dana MD | Crinetics Pharmaceuticals | 69 | |
| Wes Trotter | Kronos Bio | N/A | |
| Robert MD | Lyra Therapeutics | N/A | |
| Jeff Boerneke | Gossamer Bio | N/A | |
| Christopher Sarchi | Replimune Group | 56 | |
| JD Esq | Kura Oncology | 54 | |
| MPH DO | Kronos Bio | 60 | |
| JoAnn Suzich | Immunocore Holdings | N/A | |
| Andrew Schwendenman | Replimune Group | 49 | |
| DO Sr | Larimar Therapeutics | 63 | |
| Charles Lin | Kronos Bio | 40 | |
| Jonathan MD | Dyne Therapeutics | 39 | |
Management Performance
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.54 |
Kalvista Pharmaceuticals Leadership Team
Elected by the shareholders, the Kalvista Pharmaceuticals' board of directors comprises two types of representatives: Kalvista Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kalvista. The board's role is to monitor Kalvista Pharmaceuticals' management team and ensure that shareholders' interests are well served. Kalvista Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kalvista Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jarrod Aldom, Vice Communications | ||
| Nicole Sweeny, Chief Officer | ||
| Ryan Baker, Head Relations | ||
| Benjamin Palleiko, Chief President | ||
| Brian Piekos, Chief Officer | ||
| John McKune, VP Fin | ||
| Thomas MBA, CEO Director | ||
| Michael PharmD, Senior Development | ||
| Christopher Yea, Chief Development Officer | ||
| MD MBA, Chief Officer | ||
| Stephen Donnelly, Director Secretary | ||
| Rachel Morten, Senior QA | ||
| Edward Feener, Chief Scientific Officer | ||
| Brian JD, General Counsel |
Kalvista Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kalvista Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 280.61 M | ||||
| Shares Outstanding | 49.42 M | ||||
| Shares Owned By Insiders | 1.35 % | ||||
| Shares Owned By Institutions | 98.65 % | ||||
| Number Of Shares Shorted | 7.45 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 3.06 X | ||||
| Price To Sales | 107.42 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.